Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 56, Issue 3, Pages 1643-1645Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.05941-11
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science [22300169, DC2]
- Adaptable and Seamless Technology Transfer Program through Target-Driven RD (A-STEP) [AS231Z00132G]
- Japan Science and Technology Agency (JST)
- Smoking Research Foundation
- Keio Gijuku Academic Development Fund
- Nateglinide Memorial Toyoshima Research and Education Fund
- Grants-in-Aid for Scientific Research [22300169] Funding Source: KAKEN
Ask authors/readers for more resources
Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
